Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma Journal Article


Authors: Rivera, M.; Ghossein, R. A.; Schoder, H.; Gomez, D.; Larson, S. M.; Tuttle, R. M.
Article Title: Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma
Abstract: BACKGROUND. Radioactive iodine-refractory (RAIR) 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) positive thyroid carcinomas represent the major cause of deaths from thyroid carcinomas (TC) and are therefore the main focus of novel target therapies. However, to the authors' knowledge, the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma has not been described to date. METHODS. Metastatic tissue from RAIR PET-positive patients identified between 1996 and 2003 at the study institution were selected for histologic examination. The biopsied metastatic site corresponded to a FDG-PET positive lesion sampled within 2 years (87% of which were sampled within 1 year) of the PET scan. Detailed microscopic examination was performed on the metastatic deposit and the available primary tumors. Poorly differentiated thyroid carcinomas (PDTC) were defined on the basis of high mitotic activity (≥5 mitoses/10 high-power fields) and/or tumor necrosis. Other types of carcinomas were defined by conventional criteria. The histology of the metastases and primary were analyzed, with disease-specific survival (DSS) as the endpoint. RESULTS. A total of 70 patients satisfied the selection criteria, 43 of whom had primary tumors available for review. Histologic characterization of the metasta-sis/recurrence in 70 patients revealed that 47.1% (n = 33 patients) had PDTC, 20% (n = 14 patients) had the tall cell variant (TCV) of papillary thyroid carcinoma, 22.9% (n = 16 patients) had well-differentiated papillary thyroid carci-noma (WDPTC), 8.6% (n = 6 patients) had Hurthle cell carcinoma (HCC), and 1.4% (n = 1 patient) had anaplastic carcinomas. The histopathologic distribution of the tumor in the primaries was: PDTC, 51%; TCV, 19%; WDPTC, 23%; and widely invasive HCC, 7%. A differing histology between the primary tumor and metastasis was observed in 37% of cases (n = 16 patients). In the majority of instances (63%; 10 of 16 patients) this was noted as transformation to a higher grade. Of the primary tumors classified as PTC, 70% progressed to more aggres-sive histotypes in the metastasis. Tumor necrosis and extensive extrathyroid extension in the primary tumor were found to be independent predictors of poorer DSS in this group of patients (P = .015). Approximately 68% of the PDTC primary tumors were initially classified by the primary pathologist as better-differentiated tumors on the basis of the presence of papillary and/or follicular architecture or the presence of typical PTC nuclear features. CONCLUSIONS. Several observations can be made based on the results of the current study. The majority of metastases in patients with RAIR PET-positive metas-tases are of a histologically aggressive subtype. However, well-differentiated RAIR metastatic disease is observable. Poorly differentiated disease is underrecognized in many cases if defined by architectural and nuclear features alone. The presence of tumor necrosis was found to be a strong predictor of aggressive beha-vior, even within this group of clinically aggressive tumors. Finally, there is a significant amount of histologic plasticity between primary tumors and metastases that may reflect the genetic instability of these tumors. © 2008 American Cancer Society.
Keywords: cancer survival; controlled study; human tissue; disease-free survival; survival analysis; major clinical study; histopathology; positron emission tomography; radiopharmaceuticals; mitosis; neoplasm recurrence, local; cell differentiation; biopsy; iodine 131; radioactive iodine; iodine radioisotopes; laboratory test; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; neoplasm metastasis; thyroid carcinoma; thyroid neoplasms; tumor necrosis; fluorodeoxyglucose-positron emission tomography (fdg-pet); histopathologic characterization
Journal Title: Cancer
Volume: 113
Issue: 1
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2008-07-01
Start Page: 48
End Page: 56
Language: English
DOI: 10.1002/cncr.23515
PUBMED: 18484584
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 31" - "Export Date: 17 November 2011" - "CODEN: CANCA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ronald A Ghossein
    482 Ghossein
  2. Robert M Tuttle
    481 Tuttle
  3. Michael Rivera
    35 Rivera
  4. Daniel R Gomez
    237 Gomez
  5. Heiko Schoder
    543 Schoder
  6. Steven M Larson
    958 Larson